PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression

Post time 2026-8-15 15:25:26

journal：JAMA Oncology

Authors：Alessandro Di Federico; Samuele Compagno; Francesco Mantuano; Sara Stumpo; Andrea De Giglio; Federica Pecci; Joao V. Alessi; Xinan Wang; Francesca Sperandi; Barbara Melotti; Francesco Gelsomino; Maria A. Pantaleo; Andrea Arfè; Hossein Borghaei; Marina C. Garassino; Federico Cappuzzo; Andrea Ardizzoni; Mark M. Awad; Biagio Ricciuti

Published date：2026-7-1

DOI：10.1001/jamaoncol.2026.1548

PDF link：https://jamanetwork.com/journals ... 784081556.27949.pdf

Article link：https://doi.org/10.1001/jamaoncol.2026.1548

Article Source：American Medical Association (AMA)。

Remark：

Post time 2026-8-15 15:25:27

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[JAMA] PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression Copy